Possibility of an adverse event after vaccination against Covid-19 cannot be ruled out; states, UTs must be prepared: Center

As India plans mass vaccination against Covid-19, each state has been advised to create dedicated centers in each block to manage possible post-vaccine adverse events, from allergic reactions, high fever to more serious problems that can develop a day after administering the shot.

Authorities at 633 districts were advised to create at least one such dedicated center equipped with doctors and paramedics at each block to manage the adverse events. Detailed instructions on infection prevention and control practices during vaccination and administration of mild, severe, serious AEFI have been given to states of the Center.

Read: Center says Covid-19 cases, deaths are declining in India; warns against any laziness

“We cannot deny the possibility of an adverse event when the vaccine against Covid-19 begins. In countries where inoculation has already begun, especially in the UK, adverse events have occurred on the first day. It is essential that states and Union Territories also prepare for this, “said Rajesh Bhushan, Secretary of Union Health.

Each vaccine site has been linked to one such unit, so that in case of a serious side effect, the recipient can be taken to an administrative center quickly.

“Our existing AEFI system (adverse events after immunization) targets children and women. Most of these vaccines are administered in hospital settings. So, when treating an adult vaccine, there must be a separate AEFI administration unit such as the Covid-19 vaccines. there are new vaccines based on many kinds of platforms, ”Vinod Paul, a member of NITI Ayog and a former professor at AIIMS Delhi, said on Tuesday.

The Center initially plans to vaccinate 30 million people, starting with one million doctors and two million first-time workers. While six vaccines are currently being clinically evaluated, three manufacturers have approached the Central Organization for Drug Standardization and Control seeking authorization use.

Also Read: Decrease in household savings due to Covid-19: Survey

During the clinical trials in India, two such adverse events were recorded in Covid-19 vaccines manufactured by Bharat Biotech, Hyderabad and Serum Institute, Pune.

A preliminary investigation by the institutional ethics committee found no causal links between the vaccine and the harms and the process continues. The CDSCO regulator, however, is silent so far.

“Considering the limited information period available for (Covid-19) vaccines, it is necessary to mitigate if any fears exist other than the constructed robust evidence base for real-time efficacy,” Giridhar Babu, an epidemiologist at the Public Health Service. Foundation of India told DH, explaining the importance of setting up the AEFI network.

While the daily count of recent Covid-19 cases has dropped to 22,000 plus, India is on the verge of recording more than one crore of Covid-19 cases as the count was 99.06 lakh. The death toll is 1,43,709, of which 354 have been added in the last 24 hours.

Source